ALFA Finder| Management target | Revenue FY26 |
|---|
| Revenue growth | ~$1.25B revenue achieved as of March 2026. |
|---|---|
| Margins | Focus on uniform quality and significant capacity for batch sizes. |
| Demand visibility | Strong, exporting to more than 100 countries globally. |
| Management confidence | Confident, highlighting world-leader status in multiple API segments. |
Growth
Strong positioning with leadership in 10 of 28 APIs and strategic partnerships with 12 of Top 20 Big Pharma.
Outlook
Targeting growth through generic API leadership and expanded nutraceutical solutions as of March 2026.
Risks
Potential margin pressure if generic API pricing softens or custom synthesis project timelines shift.
Last quarter's promises, checked
Delivered
- Guided double-digit revenue growth → delivered 14% growth (₹9,712cr to ₹11,067cr) (= BEAT)
- Targeted Unit 3 operationalization → delivered steady production increase and GMP space freeing (= BEAT)
- Maintain supply reliability despite logistics crisis → delivered zero production stoppages (= BEAT)
Partly delivered
- Kakinada expansion (₹1,500cr) → delivered ₹600cr capitalized to date (= PARTIAL)
- Peptide business validation → delivered several fragments validated, commercialization pending customer approval (= PARTIAL)
Missed
- Historical margin levels (37-38%) → delivered ~32% (= MISS)
Earnings Call Transcript filed with NSE, NSE: DIVISLAB. Summary written with AI assistance from the document.
Divi's Laboratories Ltd: key numbers
- Share price
- ₹11,442.00
- Market cap
- ₹3,03,749 Cr
- Revenue (annual)
- ₹10,560 Cr
- Net profit (annual)
- ₹2,568 Cr
- P/E (TTM)
- 90.3×Sector 43.7×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 20.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Divi's Laboratories Ltd
All →Divi's Laboratories Investor Presentation: Key Takeaways
Q2 FY27 consolidated PAT ₹1,127 cr (+64% YoY) on total income ₹3,770 cr (+32%). H1 PAT ₹2,029 cr (+64%). CS is 62% of H1 sales; heavy capex cycle underway.
Divi's Laboratories Q2 FY27 Results: Net Profit ₹1,127 Cr, Up 63.6% YoY
Divi's Laboratories Ltd reported revenue from operations of ₹3,676 Cr (+35.4% YoY) and net profit of ₹1,127 Cr (+63.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,127 Cr · +63.6% YoY
Divi's Laboratories Board Meeting Date
Divi's Laboratories will hold a board meeting on November 07, 2026, to approve unaudited standalone and consolidated financial results for the quarter ended September 30, 2026.
Divi's Laboratories Other Announcement
Divis Laboratories Ltd has submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI Regulation 31.
Divi's Laboratories Other Announcement
Immediate relatives of the company purchased 462 shares for a total consideration of Rs. 0.43 Crore in the open market.
- Value
- ₹0.43 Cr
Divi's Laboratories Other Announcement
Divis Laboratories Ltd reported a share pledge by Designated Person Nimmagadda Venkata Anirudh involving securities valued at ₹3.33 Crore. Additionally, Joshita Divi acquired shares worth ₹0.96 Crore via market purchase.
- Value
- ₹4.29 Cr